Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β

Multiple Sclerosis Journal

Volumn 19, Issue 7, 2013, Pages 885-890

  Bǎlaşa, Rodica ^a   Bajko, Zoltan ^a   Huţanu, Adina ^a,b  

^a University Emergency County Hospital   (Romania)

^b UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

binding antibodies to interferon; interferon treatment; interleukin 17; Multiple sclerosis; nonresponder to interferon

Indexed keywords

BETA INTERFERON; INTERLEUKIN 17;

ADULT; ANTIGEN BINDING; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSPECTIVE STUDY; RELAPSE; REMISSION; TH17 CELL; TREATMENT RESPONSE;

EID: 84872542057     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512468497     Document Type: Article

References (34)

1. Rudick RA, Polman CH. Current approach to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 2009 ; 8: 545-559
2. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol. 2000 ; 47: 707-717
3. Hesse D, Krakauer M, Lund H, et al. Breakthrough disease during interferon-β therapy in MS. Neurology. 2010 ; 74: 1455-1462
4. Axtell RC, Raman C, Steinman L. Interferon-β exacerbates Th17-mediated inflammatory disease. Trends Immunol. 2011 ; 32: 272-277
5. Bǎlaşa R, Huţanu A, Bajko Z, et al. Does the serum IL-17 titer influence the efficacy of interferon-β treatment in multiple sclerosis patients?. Rev Rom Med Lab. 2011 ; 19: 381-390
6. Brucklacher-Waldert V, Stuerner K, Kloster M, et al. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain. 2009 ; 132: 3329-3341
7. Bǎlaşa R, Huţanu A, Feier C, et al. Incidence and clinical significance of binding antibodies and their relationships with neutralising antibodies, both induced by interferon-β treatment in multiple sclerosis patients. Rev Rom Med Lab. 2010 ; 18: 39-50
8. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol. 2005 ; 58: 840-846
9. Mǎruşteri M, Bacârea V. Comparing groups for statistical differences: How to choose the right statistical test?. Biochem Medica. 2010 ; 20: 15-32
10. Kieseir BC.. Assessing long-term effects of disease-modifying drugs. J Neurol. 2006 ; 253: 23-30
11. Durelli L, Conti L, Clerico M, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β. Ann Neurol. 2009 ; 65: 499-509
12. Gilli F, Bertolotto A, Sala A. Biological responsiveness to first injections of interferons beta in patients with multiple sclerosis. J Neuroimmunol. 2005 ; 158: 195-203
13. Pozzilli C, Prosperini L. Clinical markers of therapeutic response to disease modifying drugs. Neurol Sci. 2008 ; 29: 211-213
14. Bertolotto A, Gilli F. Interferon-beta responders and non-responders. A biological approach. Neurol Sci. 2008 ; 29: 216-217
15. Axtell RC, De Jong A, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis. Nat Med. 2010 ; 16: 406-412
16. Bushnell SE, Zhao Z, Stebbins CC, et al. Serum IL-17F does not predict poor response to IM IFN-β 1a in relapsing remitting MS. Neurology. 2012 ; 79: 531-537
17. Confavreux C, Compston A Mc Alpine's multiple sclerosis. 4 th ed.Philadelphia: Churchill Livingstone Elsevier, 2006, pp.183-272. Compston A Confavreux C Lassmann H, ed. Philadelphia: Churchill Livingstone Elsevier ; 2006: 183-272.
18. Michatowska-Wender G, Biernacka-Lukanty J, Lasik Z, et al. Interleukin 17 receptor in multiple sclerosis patients treated with interferon β-1a. Folia Neuropathol. 2011 ; 49: 138-141
19. Frisullo G, Nociti V, Iorio R, et al. IL17 and IFN-γ production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Cytokine. 2008 ; 44: 22-25
20. Hedegaard CJ, Krakauer M, Bendtzen K, et al. T helper cell type I (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology. 2008 ; 125: 161-169
21. Ramgolam VS, Sha Y, Jin J, et al. IFN-beta inhibits human Th17 cell differentiation. J Immunol. 2009 ; 183: 5418-5427
22. Fort MM, Cheung J, Yen D, et al. IL-25 induced IL-4, IL-5 and IL13 and Th2 - associated pathologies in vivo. Immunity. 2001 ; 15: 985-995
23. Jadidi-Niaragh F, Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol. 2011 ; 74: 1-13
24. Comabella M, Lünemann JD, Río J, et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain. 2009 ; 132: 3353-3365
25. Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells in glial cells is associated with active disease in multiple sclerosis. Amer J Pathol. 2008 ; 172: 146-155
26. Graber JJ, Allie SR, Mullen KM, et al. Interleukin-17 in transverse myelitis and multiple sclerosis. J Neuroimmunol. 2008 ; 196: 124-132
27. Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007 ; 13: 1173-1175
28. Gold R, Luhder F. Interleukin-17-extended features of a key player in multiple sclerosis. Amer J Pathol. 2008 ; 172: 8-10
29. Pachner AR, Oger J, Palace J. The measurement of antibodies binding to IFN-β in MS patients treated with IFN-β. Neurology. 2003 ; 61: S18 - S20
30. Pappas DJ, Oksenberg JR. Multiple sclerosis pharmacogenomics: maximizing efficacy of therapy. Neurology. 2010 ; 74: S62 - S69
31. Goodin DS, Hartung H-P, O'Connor P, et al. Neutralizing antibodies to interferon beta-1b in multiple sclerosis: a clinic-radiolographic paradox in the BEYOND trial. Mult Scler J. 2012 ; 18: 181-195
32. Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology. 2005 ; 65: 33-39
33. Bielokova B, Martin R. Development of biomarkers in multiple sclerosis. Brain. 2004 ; 127: 1463-1478
34. Steinman L.. A rush to judgment on Th17. J Exp Med. 2008 ; 205: 1517-1522